Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without d...
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors
About this item
Full title
Author / Creator
Harutani, Yuhei , Ozawa, Yuichi , Murakami, Eriko , Sato, Koichi , Oyanagi, Jun , Akamatsu, Hiroaki , Yoshikawa, Takanori , Shibaki, Ryota , Sugimoto, Takeya , Furuta, Katsuyuki , Teraoka, Shunsuke , Tokudome, Nahomi , Hayata, Atsushi , Ueda, Hiroki , Nakanishi, Masanori , Koh, Yasuhiro and Yamamoto, Nobuyuki
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
While PD-1/L1 inhibitors are characterized by durable tumor control, they also prolong survival without prolongation of progression-free survival (PFS) in part of patients. However, little is known about the factors and mechanisms involved in this. Between December 2015 and September 2018, 106 patients with advanced non-small cell lung cancer treat...
Alternative Titles
Full title
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991224
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991224
Other Identifiers
ISSN
0340-7004
E-ISSN
1432-0851
DOI
10.1007/s00262-022-03141-4
